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Abstract 
Background: Berberine (BBR), as a new medicine for hyperlipidemia, can reduce the blood lipids in patients. Mecha‑
nistic studies have shown that BBR activates the extracellular‑signal regulated kinase pathway by stabilizing low‑den‑
sity‑lipoprotein receptor mRNA. However, aside from inhibiting the intestinal absorption of cholesterol, the effects of 
BBR on other metabolic pathways of cholesterol have not been reported. This study aimed to investigate the action of 
BBR on the excretion of cholesterol in high‑fat diet‑induced hyperlipidemic hamsters.
Methods: Golden hamsters were fed a high‑fat diet (HFD) for 6 weeks to induce hyperlipidemia, followed by oral 
treatment with 50 and 100 mg/kg/day of BBR or 10 and 30 mg/kg/day of lovastatin for 10 days, respectively. The 
levels of total cholesterol (TC), triglyceride (TG), low‑density lipoprotein cholesterol (LDL‑C), transaminases, and 
total bile acid in the serum, liver, bile and feces were measured using an enzyme‑linked immunosorbent assay. The 
cholesterol (as well as coprostanol) levels in the liver, bile and feces were determined by gas chromatography–mass 
spectrometry.
Results: The HFD hamsters showed significantly hyperlipidemic characteristics compared with the normal ham‑
sters. Treatment with BBR for 10 days reduced the serum TC, TG and LDL‑C levels in HFD hamsters by 44–70, 34–51 
and 47–71 %, respectively, and this effect was both dose‑ and time‑dependent. Initially, a large amount of cho‑
lesterol accumulated in the hyperlipidemic hamster livers. After BBR treatment, reductions in the liver cholesterol 
were observed by day 3 and became significant by day 7 at both doses (P < 0.001). Meanwhile, bile cholesterol was 
elevated by day 3 and significantly increased at day 10 (P < 0.001). BBR promoted cholesterol excretion from the liver 
into the bile in hyperlipidemic hamsters but not in normal hamsters, and these results provide a link between the 
cholesterol‑lowering effect of BBR with cholesterol excretion into the bile.
Conclusions: We conclude that BBR significantly promoted the excretion of cholesterol from the liver to the bile in 
hyperlipidemic hamsters, which led to large decreases in the serum TC, TG and LDL‑C levels. Additionally, compared 
with lovastatin, the BBR treatment produced no obvious side effects on the liver function.
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Background
Berberine (BBR) is a medicinal alkaloid that is isolated 
from Coptis chinensis and has been used orally for dec-
ades in China as a safe over-the-counter (OTC) drug to 
treat diarrhea [1]. In recent years, in addition to its anti-
bacterial effect [2–5], this natural compound has been 
increasingly studied for its effects against various dis-
eases, including hyperlipidemia [6], diabetes [7, 8], and 
nervous system [9] and cardiovascular diseases [10–12]. 
BBR has obvious effects on lowering the plasma total 
cholesterol (TC), triglyceride (TG) and low-density lipo-
protein cholesterol (LDL-C) levels, and these effects may 
be better in some aspects than those achieved when using 
simvastatin and atorvastatin [13]. The mechanism of its 
cholesterol-lowering activity was found to be related to 
its effects on elevating the low-density lipoprotein recep-
tor (LDLR) expression by stabilizing LDLR message ribo-
nucleic acid (mRNA) and was completely distinct from 
the statin mechanism of inhibiting 3-hydroxy-3-meth-
ylglutaryl-coenzyme A (HMG-CoA) reductase [1]. In 
addition, the same groups conducted further studies, 
mainly in HepG2 cells, and observed similar effects of 
BBR [14, 15]. Since then, an increasing number of studies 
in numerous different rodent models, cells and patients 
with hyperlipidemia have been conducted. In addition to 
up-regulating the LDLR, BBR inhibited lipid synthesis in 
human hepatocytes via the activation of AMP-activated 
protein kinase (AMPK) [16]. BBR was also reported to 
be effective in inhibiting 3T3-L1 adipocyte accumulation 
and differentiation through the peroxisome proliferator-
activated receptor (PPAR) γ pathway, and these results 
suggested that BBR worked as an inhibitor of PPAR γ and 
α on multiple molecular targets [17, 18]. The blood free 
fatty acid (FFA) level was decreased, and the activity of 
lipoprotein lipase was increased in hyperlipidemic and 
insulin-resistant rats after the administration of BBR [19]. 
A recent study showed that BBR decreased the blood 
cholesterol level in hypercholesterolemic rats by inhibit-
ing intestinal absorption, followed by decreasing entero-
cyte cholesterol uptake and secretion [20]. Apart from 
LDLR-mediated LDL-C clearance in the liver, cholesterol 
homeostasis includes several other biological processes, 
such as cholesterol absorption, cholesterol biosynthesis, 
cholesterol excretion, bile acid biosynthesis and secre-
tion. However, in addition to the intestinal absorption of 
cholesterol, the effects of BBR on these metabolic path-
ways should be shown. We know that cholesterol excre-
tion from the liver to the bile is collectively controlled by 
various factors. Therefore, to further elucidate the cho-
lesterol-lowering mechanism of BBR, we asked whether 
BBR could impact this important process.
Recent pharmacology studies have indicated that BBR 
possesses a good cholesterol-lowering activity and is a 
safer treatment than other hypolipidemic drugs [21]; 
therefore, BBR has become an effective hypolipidemic 
drug with potential benefits for the treatment of hyper-
lipidemia and other metabolic syndromes. Considering 
the lack of evident side effects reported from the clinical 
use of BBR [22] and the reported side effects of statins, 
including muscle pain, fatigue, and weakness, accom-
panied by an increase in creatine phosphokinase (CPK) 
and liver transaminase [23–25], it is meaningful to com-
pare the lipid-lowering efficacies of BBR and lovasta-
tin as well as their side effects on the liver in our study. 
Based on the effective doses in hamsters (50 and 100 mg/
kg/day) [1], we performed this study with high-fat diet-
induced hyperlipidemic hamsters by treating them with 
BBR and lovastatin for 10 days, respectively, to study the 
effect of BBR on the excretion of cholesterol and provide 




Berberine chloride, lovastatin and 5α-cholestane were 
purchased from J&K Scientific Ltd (Beijing, China). Cho-
lesterol and coprostanol were supplied by the National 
Institute for the Control of Pharmaceutical and Biological 
Products (Beijing, China) and Shanghai Huicheng Bio-
technology Co., Ltd. (Shanghai, China), respectively. The 
purity of all standards listed above was more than 98 %. 
A package of kits for CHO, TG, LDL-C, alanine ami-
notransferase (ALT), aspartate aminotransferase (AST) 
and γ-glutamyltransferase (GGT) were purchased from 
BioSino Bio-Technology & Science Inc. (Beijing, China). 
The total bile acid (TBA) assay kit was obtained from the 
Nanjing Jiancheng Bioengineering Institute (Nanjing, 
China). High-performance liquid chromatography-grade 
n-hexane, ethyl acetate and methanol were obtained from 
J&K Scientific Ltd (Beijing, China). The distilled water 
was Wahaha purified water (Hangzhou, China).
Equipment
A Shimadzu gas chromatograph mass spectrometer 
(GC–MS, Shimadzu Cooperation, Kyoto, Japan), EnSpire 
multimode microplate reader (PerkinElmer, Waltham, 
MA, USA), THZ-100-type incubation shaker (Shanghai, 
China), TG18G-II desktop universal high-speed cen-
trifuge (Hunan Kaida Scientific Instruments Co., Ltd, 
Hunan, China), XW-80A miniature vortex mixers (Jin-
tan Super Blue Instrument Manufacturing Co., Jintan, 
Ltd, China) and a MD200-2 nitrogen sweep blowing 
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instrument (Hangzhou Dian Sheng Instrument Co., Ltd, 
Hangzhou, China) were used.
Animals and study design
Eight-week-old male Syrian Golden Hamsters weigh-
ing 110–140 g (Vital River Laboratory Animal Technol-
ogy Co., Ltd., Beijing, China) were housed in a controlled 
environment (21 ± 2 °C, 12-h light/dark cycle) at six per 
cage with free access to food and water during the accli-
matization and study periods. The animal usage and 
experimental protocols were approved by the Laborato-
ries’ Institutional Animal Care and Use Committee of the 
Chinese Academy of Medical Sciences and Peking Union 
Medical College. The research was conducted in accord-
ance with all guidelines and ethics of the Chinese Council 
on Animal Care.
One hundred and twenty-four hamsters were accli-
matized for 7  days in their cages before the start of the 
study. All animals were then randomly separated into 
two groups according to their weights: the normal con-
trol group (thirty-four animals) and the hyperlipidemia 
model group (ninety animals). The animals that served 
as the normal control group were fed the standard diet 
ad  libitum, whereas the hyperlipidemia model ham-
sters were fed a high-fat diet (HFD) daily for a period 
of 6  weeks to induce hyperlipidemia. The high-fat diet 
(Beijing HFK Bioscience Co., Ltd, China) was composed 
of 83.0 % standard diet, 15.0 % fat, 1.0 % cholesterol and 
1.0 % sodium cholate [26].
At the end of 6 weeks, all animals were fasted for 12 h. 
Blood was collected, and the serum was obtained to 
measure the serum levels of TC, TG and LDL-C. The ani-
mals fed with a high fat diet showed significantly higher 
levels of TC, TG and LDL-C than the animals in the nor-
mal control group. According to their serum TC levels, 
the hamsters that were fed the normal diet (ND) were 
randomly allocated into two groups: 8 animals served 
as the ND control group, and 26 animals were treated 
with BBR (100  mg/kg/day). The hamsters that were fed 
the HFD were then randomly allocated into five groups: 
8 animals served as the HFD control group, 26 animals 
were treated with BBR (50 mg/kg/day), 26 animals were 
treated with BBR (100  mg/kg/day), 15 animals were 
treated with lovastatin (10  mg/kg/day) and 15 animals 
were treated with lovastatin (30 mg/kg/day) [27].
All animals were orally administered the placebo, BBR 
or lovastatin, which was dissolved by saline into liquid 
suspension, in the morning for 10 days. After the animals 
were fasted for 12  h, the blood samples were obtained 
from posterior orbital venous plexus at 0, 3, 5, 7, and 
10  days (n =  6 for each time point) by immediate cen-
trifugation at 5,000 r/min for 5 min to obtain the serum 
samples. Feces were collected at the same time points. 
The hamsters were anesthetized for the collection of bile 
and liver samples. All samples were stored at −20 °C for 
the subsequent analyses.
Serum lipid, ALT, AST and GGT levels
The concentration of TC, TG, LDL-C, ALT, AST and 
ALT in serum was determined at the end of the treat-
ment using enzymatic kits.
Cholesterol in bile, liver and feces
The liver samples obtained from the animals were washed 
with saline and dried. After weighing, they were homog-
enized with 2 volumes [v (mL)/w (g)] of saline. The bile 
and liver homogenates (50  μL) were extracted with 
300 μL of ethyl acetate after the addition of 10 μL of an 
internal standard solution (100 μg/mL of 5α-cholestane 
in methanol) and 10  μL of methanol, respectively. To 
prepare the cholesterol standard curve, the bile and liver 
homogenates (infinitely diluted with saline, 50 μL) were 
extracted with 300 μL of ethyl acetate after the addition 
of 10 μL of an internal standard and 10 μL of a choles-
terol standard working solution (prepared at a serial con-
centrations of 0.01, 0.1, 0.2, 1, 2, 10, 20, 100, and 200 μg/
mL by dissolving in methanol), respectively. The samples 
were mixed using a vortex mixer for 20  min, followed 
by centrifuging at 5,000×g for 5  min. The supernatant 
was dried under N2 flow at 40  °C [28], and the residue 
was reconstituted with 200 μL of n-hexane and filtered 
through a 0.22-μm micropore membrane. An aliquot of 
1 μL was injected into the GC–MS system.
The feces samples were triturated before weighing and 
dissolved with 10 volumes [v (mL)/w (g)] of methanol, 
followed by ultrasonic extraction for 30  min and cen-
trifugation at 10,000  r/min for 10 min. The supernatant 
from the feces (200 μL) was extracted with 1 mL of ethyl 
acetate after the addition of 10 μL of an internal standard 
(100  μg/mL of 5α-cholestane), 10  μL of methanol and 
500 μL of distilled water. To prepare the standard curve 
of cholesterol and coprostanol, the supernatants from 
the feces (infinitely diluted with methanol, 200 μL) were 
extracted with 1 mL of ethyl acetate after the addition of 
10 μL of an internal standard and 10 μL of a cholesterol 
and coprostanol standard working solution (prepared at 
a serial concentrations of 0.5, 2.5, 5, 25, 50, 125, 250, and 
500 μg/mL by dissolving in methanol), respectively. The 
samples were mixed using a vortex mixer for 20 min and 
centrifuged at 5,000×g for 5  min. The supernatant was 
dried under N2 flow at 40 °C, and the residue was recon-
stituted with 200 μL of n-hexane and filtered through a 
0.22-μm micropore membrane. An aliquot of 1 μL was 
injected into the GC–MS system.
A GC–MS method was used to determine the cho-
lesterol (as well as coprostanol) levels in bile, liver and 
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feces. A capillary column (AT-1701, 30  m  ×  0.25  mm, 
and 0.25 μm phase thickness) was used, and high purity 
helium was used as a carrier gas at a constant flow rate 
of 1 mL/min. The temperature program started at 60 °C, 
was increased to 270 °C after 2 min at a rate of 20 °C/min, 
and was maintained at that temperature for 12.5  min. 
The sample was injected in a split-less mode. The injector 
temperature and transfer linear temperatures were set to 
260 and 265 °C, respectively. The mass spectrometer was 
operated in the electron impact ionization mode with 
70 eV, and the ion source temperature was set to 230 °C.
TBA in bile, liver and feces
The concentration of TBA in bile, liver and feces was 
determined at the end of the treatment using enzymatic 
kits.
Statistical analysis
The statistical analysis was performed using Graph Pad 
Prism 5 software (Graph Pad Software, San Diego, CA, 
USA). The data were analyzed by one-way analysis of var-
iance (ANOVA) followed by Dunnett’s post hoc test or 
two-way ANOVA plus Bonferroni’s post-test, as appro-
priate. The results are presented as the mean ± standard 
deviation (S.D.). P-values equivalent to a significance 
level of 0.05 were considered statistically significant.
Results and discussion
Serum lipid levels
At the end of 6  weeks, the serum TC, TG and LDL-C 
levels were increased by 3.86-, 3.32- and 2.94-fold 
(P  <  0.001), respectively, in the HFD group compared 
with the normal control group (Table 1). The oral admin-
istration of BBR and lovastatin for 10  days resulted in 
dose- and time-dependent decreases in the serum TC, 
TG and LDL-C levels in the hyperlipidemic hamsters 
(Fig.  1a–c). After the 10-day treatment, 50  mg/kg/day 
BBR reduced the TC, TG and LDL-C levels in the hyper-
lipidemic hamsters by 44 % (P < 0.001), 34 % (P < 0.05), 
and 47  % (P  <  0.001), respectively, and 100  mg/kg/day 
BBR reduced the TC, TG and LDL-C levels by 70  % 
(P < 0.001), 51 % (P < 0.001), and 71 % (P < 0.001), respec-
tively, compared with the animals in the HFD control 
group. In contrast, 10  mg/kg/day lovastatin decreased 
the TC, TG and LDL-C levels by 25 % (P < 0.01), 21 %, 
and 44 % (P < 0.001), respectively, and 30 mg/kg/day lov-
astatin decreased the TC, TG and LDL-C levels by 49 % 
(P < 0.001), 41 % (P < 0.01), and 55 % (P < 0.001), respec-
tively. At day 10, the serum TC levels in the lovastatin-
treated HFD hamsters (10 mg/kg/day) were significantly 
different from those of the BBR-treated HFD (100  mg/
kg/day) (P < 0.01). However, there was no significant dif-
ference among the TC, TG and LDL-C serum levels of 
animals in the BBR-treated ND group at each time point. 
The results described above show that BBR has an effec-
tive role in lowing the serum TC, TG and LDL-C levels 
and that BBR may be superior to lovastatin in lowering 
the serum TC levels. Additionally, BBR has no effect on 
the serum TC, TG and LDL-C levels in normal hamsters.
Serum ALT, AST and GGT levels
Measurements of the serum ALT, AST and GGT levels 
were performed to evaluate the effect of BBR and lov-
astatin on liver function. Significantly elevated serum 
ALT and AST levels were observed in the lovastatin-
treated HFD hamsters (30  mg/kg/day) at day 10 com-
pared with the HFD control group at day 0 (Fig.  2a, b), 
which were increased by 2.0-fold (P < 0.01) and 2.1-fold 
(P  <  0.001), respectively, whereas the BBR-treated HFD 
group (100  mg/kg/day) showed no significant differ-
ences throughout the measurement period. The serum 
ALT and AST levels of the lovastatin-treated HFD group 
(30 mg/kg/day) were significantly different from those of 
the BBR-treated HFD group (100  mg/kg/day) at day 10 
(P  <  0.01 and P  <  0.001, respectively). Thus, 30  mg/kg/
day lovastatin treatment resulted in serum ALT and AST 
levels in the hyperlipidemic hamsters deviating from the 
normal range, which indicated that it caused a certain 
degree of liver damage. Nevertheless, our data show that 
no observable damage was caused by BBR in both the 
ND and HFD hamsters. BBR treatment even improved 
liver function by reducing the levels of ALT and ALT [1]. 
There was no significant difference among the groups in 
the serum GGT levels (Fig. 2c).
Reduced cholesterol in the liver and increased cholesterol 
in bile
This is the first study examining the cholesterol in bile in 
hyperlipidemic animals treated with BBR. To investigate 
the effect of BBR on cholesterol excretion in our study, 
both normal and hyperlipidemic hamsters were treated 
with BBR, and we determined the changes of cholesterol 
in the liver, bile and feces at each time point based on the 
results of the serum lipid levels. Similar to the serum lipid 
Table 1 Changes in  the serum TC, TG and  LDL-C levels 
in HFD hamsters after 6 weeks
***p < 0.001 compared with the normal control group; Normal control animals, 
n = 20; HFD animals, n = 20. The statistical analysis was performed using a two-
tailed Student’s t test.
TC (mmol/L) TG (mmol/L) LDL-C (mmol/L)
Normal control 0.87 0.72 0.35
HFD 3.36*** 2.39*** 1.03***
Fold change 3.86 3.32 2.94
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levels in normal hamsters, the cholesterol in the liver and 
bile in the BBR-treated ND group showed no significant 
differences throughout the measurement period (Fig. 3a, 
b), which indicated that BBR did not affect the choles-
terol levels in the normal hamsters.
In the hyperlipidemic hamsters, the liver cholesterol 
level was significantly increased compared to the ND 
control hamsters (Fig. 3c). A large amount of cholesterol 
may be accumulated in the liver due to the high-fat diet, 
according to a previous study that used H&E staining of 
the liver tissue and showed obvious fat droplet accumu-
lation in livers of HFD-fed hamsters [26]. After the BBR 
treatment, reductions in liver cholesterol in HFD ham-
sters were observed by day 3 and became significant by 
day 7 at both doses (P < 0.001). The bile cholesterol was 
elevated by day 3, and both BBR-treated HFD groups 
showed significantly higher bile cholesterol levels at day 
10 compared with the HFD control group (P < 0.01 and 
P < 0.001, respectively, Fig. 3d). The BBR effect was dose-
dependent in both the levels of liver and bile cholesterol. 
Moreover, the level of liver cholesterol in the HFD group 
at day 10 showed no significant differences compared 
with the ND control group at day 0 (Fig. 3c). We conclude 
that BBR has a remarkable effect on promoting choles-
terol excretion from the liver into the bile in hyperlipi-
demic hamsters, and these results provide a link between 
the cholesterol-lowering effect of BBR with its activity in 
promoting cholesterol excretion into the bile. Addition-
ally, the liver and bile cholesterol levels of both lovasta-
tin-treated HFD hamsters were significantly different 
than the 100  mg/kg/day BBR-treated HFD hamsters at 
day 10 (P < 0.001). These results showed that lovastatin 
did not significantly decrease the liver cholesterol level or 
increase the bile cholesterol level and revealed that lovas-
tatin has no obvious effect on promoting the excretion of 
cholesterol (Fig. 3e, f ).
Finally, we asked whether the bile cholesterol could be 
excreted into the feces. Studies on cholesterol generally 
make it clear that cholesterol is primarily transformed 
into coprostanol by the intestinal microbiota [29–31]. 
Coprostanol comprised the largest amount of the feces 
and was produced from cholesterol principally by direct 
Fig. 1 Serum lipid levels at each time point. (a) BBR and lovastatin significantly reduced the serum TC levels in the hyperlipidemic hamsters. The 
serum TC levels in the lovastatin‑treated HFD hamsters (10 mg/kg/day) were significantly different from those of the BBR‑treated HFD hamsters 
(100 mg/kg/day) at day 10. (b) BBR and lovastatin significantly reduced the serum TG levels in the hyperlipidemic hamsters. (c) BBR and lovasta‑
tin significantly reduced the serum LDL‑C levels in the hyperlipidemic hamsters. The data are shown as the mean ± SD. *P < 0.05, **P < 0.01 and 
***P < 0.001 vs the ND controls; ##P < 0.01 vs the BBR‑treated HFD hamsters (100 mg/kg/day).
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saturation of the 5, 6-double bond of cholesterol [32]. To 
clarify this point, we assessed the levels of cholesterol and 
coprostanol in feces. Compared with the ND hamsters, 
the level of cholesterol in the HFD hamsters’ feces at day 
0 was significantly increased (P  <  0.001), which may be 
due to a certain proportion of cholesterol in the high-
fat diet. From day 0 to day 3, increased cholesterol and 
decreased coprostanol were observed in the feces of the 
HFD hamsters (Fig. 3g). From day 3 to day 10, decreased 
cholesterol and significantly increased coprostanol were 
observed (P < 0.001), which indicated that the bile cho-
lesterol was ultimately excreted into the feces, primarily 
in the form of coprostanol.
TBA in liver, bile and feces
TBA is synthesized and catabolized from cholesterol by 
the liver. The levels of TBA in the liver, bile and feces 
were determined at the end of the study to demon-
strate that BBR has evident effects on another aspect 
of cholesterol. As a result, BBR caused a significant 
increase in liver TBA in hyperlipidemic animals com-
pared with the HFD control group (Fig.  4a), and the 
level of bile TBA was markedly increased (Fig.  4b). 
The liver is the main organ of cholesterol synthesis and 
clearance. When a large amount of cholesterol accu-
mulated in the liver, BBR promoted the transforma-
tion of cholesterol to bile acids to a certain extent, thus 
resulting in more rapid excretion of cholesterol. How-
ever, in the feces, the level of TBA was increased in 
the BBR-treated HFD animals from day 0 to day 3 and 
significantly decreased from day 3 to day 10 (P < 0.001, 
Fig. 4c). After TBA is secreted by the liver cells into the 
bile, it enters the intestine with the bile flow and is then 
hydrolyzed to other forms of bile acid by the action of 
the intestinal microbiota. Finally, 97  % of the bile acid 
is returned to the liver after intestinal reabsorption. The 
whole process of the bile acid cycle is extremely compli-
cated, and further study is necessary.
Fig. 2 Effects of BBR and lovastatin on the liver function of hyperlipidemic hamsters. (a) Lovastatin (30 mg/kg/day) increased the serum ALT level 
by 2.0‑fold at day 10 compared with the HFD control group at day 0, whereas the BBR (100 mg/kg/day) group showed no significant differences 
over the entire period. (b) Lovastatin (30 mg/kg/day) elevated the serum AST level by 2.1‑fold at day 10 compared with the HFD control group at 
day 0, whereas the BBR (100 mg/kg/day) group showed no significant differences over the entire period. (c) There were no significant differences 
in the serum GGT levels in any of the groups. The data are shown as the mean ± SD. **P < 0.01 and ***P < 0.001 vs the HFD controls; ##P < 0.01 and 
###P < 0.001 vs the BBR‑treated HFD hamsters (100 mg/kg/day).
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In general, this is the first study to determine the cho-
lesterol in bile in BBR-treated hyperlipidemic animals. A 
high-fat diet was used to induce hyperlipidemia in ham-
sters to study the effects of BBR on cholesterol excretion. 
Using this hamster model, we demonstrated that BBR 
significantly promoted cholesterol excretion from the 
liver into the bile and finally excreted it into the feces, 
primarily in the form of coprostanol, which led to large 
decreases in the serum TC, TG and LDL-C levels. A 
recent study showed that BBR promoted the excretion 
of neutral and acidic sterols [33]. In another study, BBR 
lowered the blood cholesterol levels by inhibiting the 
intestinal absorption, with additional support provided 
by strong correlations between the cholesterol absorp-
tion rates and the plasma total or non-HDL cholesterol 
levels [20]. These are all different mechanisms that are 
distinct from the reported enhancement of the previ-
ously reported LDLR-mediated liver LDL-C clearance 
mechanism [1]. The most widely used drugs that sta-
bilize and elevate LDLR are the PCSK 9 inhibitors, and 
BBR decreases the PCSK 9 mRNA and protein levels in 
a time- and dose-dependent manner. This was not due 
to increased degradation of the PCSK 9 mRNA but was 
most likely due to the decreased transcription of the 
PCSK 9 gene [34]. Our results did help prove that BBR 
is a multi-target lipid-lowering drug. We also compared 
BBR with lovastatin in several aspects, including the 
effects of lowering the serum lipid levels, inducing liver 
damage and promoting the excretion of cholesterol. As 
a result, our data show that BBR has an effective role in 
lowering the serum TC, TG and LDL-C levels, which 
may be superior to lovastatin in lowering the serum 
TC level. Moreover, 30  mg/kg/day lovastatin resulted 
in a certain degree of liver damage, whereas neither 
dose of BBR damaged the liver. Nevertheless, due to the 
poor absorption of BBR in  vivo, we chose the effective 
doses of BBR as 50 and 100 mg/kg/day based on previ-
ous reports [1, 13]. Increasing the dose of lovastatin to 
be equal to BBR, with a dose of 50  mg/kg/day or even 
100  mg/kg/day, will exceed the safe dose range of lov-
astatin. Therefore, the doses of BBR and lovastatin used 
here were not consistent [1, 28]. In addition, this may be 
the first study to elucidate that BBR can promote cho-
lesterol excretion into the bile. Therefore, it will be very 
Fig. 3 Reduced cholesterol in the liver and increased cholesterol in the bile after the BBR treatment. (a) The liver cholesterol levels in the BBR‑
treated ND hamsters. (b) The bile cholesterol levels in the BBR‑treated ND hamsters. (c) Reductions in the liver cholesterol levels of the HFD hamsters 
were observed by day 3 and became significant by day 7 at both doses. (d) BBR resulted in significantly higher cholesterol levels in both BBR‑treated 
HFD groups at day 10 than the HFD control group. (e) Lovastatin did not significantly decrease the cholesterol levels in the HFD hamster livers. (f) 
Lovastatin did not significantly increase the cholesterol levels in the HFD hamster bile. (g) In the feces, BBR decreased the levels of cholesterol, but 
significantly increased the levels of coprostanol from day 3 to day 10. The data are shown as the mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001 
vs the ND controls (c, e and g) or the HFD controls (d, f); ###P < 0.001 vs the BBR‑treated HFD hamsters (100 mg/kg/day).
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helpful to explore the cholesterol-lowering mechanism 
of BBR in the future.
Conclusions
We conclude that BBR significantly promoted the excre-
tion of cholesterol from the liver to the bile in hyper-
lipidemic hamsters, which led to large decreases in the 
serum TC, TG and LDL-C levels. There were no obvious 
side effects due to the serum transaminases after the BBR 
treatment, although high doses of lovastatin could influ-
ence the liver function to a certain extent. BBR is sug-
gested to be useful as a monotherapy or in combination 
with statins.
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